New Alzheimer’s Treatment

New Alzheimer’s Treatment

Neurology | Faculty of Medicine
Share Story Related Content Add to my report

A unique new treatment for Alzheimer’s Disease could put Canada—and UBC—in the history books for helping to prevent this killer disease that now affects one in 11 Canadians over the age of 65.

UBC Faculty of Medicine neuroscientist Neil Cashman, a member of the Brain Research Centre at UBC and Vancouver Coastal Health, has developed an immune-based treatment that targets the catalyst in triggering Alzheimer’s—a small clump of toxic protein molecules that forms plaques in the brain. While previous treatments targeted the plaques themselves, this new treatment aims to eradicate the toxin before it can cause any damage. The catch? The toxic version of the protein only lives a short time.

But, by producing antibodies that specifically attach to the toxic protein, Dr. Cashman, who is now working with Canadian biopharmaceutical company Cangene to develop a treatment, has created an effective early diagnostic for the disease, and has laid the groundwork for the development of a preventative vaccine.

“This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic,” says J.P. Heale, Associate Director of UBC’s University-Industry Liaison Office. “The partnerships developed to advance Dr. Cashman’s outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance.”

 

 

Related Content

“This is an all-Canadian solution and an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance.” – J.P. Heale, Associate Director of UBC’s University-Industry Liaison Office

Associated Commitment

Research Excellence
Dr. Neil Cashman in his lab Credit: Martin Dee

Associated Campus

Vancouver Campus

Twitter

RT @CRubino10: A small achievement but still a great feeling when your abstract gets accepted. Excited to finally share my research showing…
5 Mar, 19
RT @AttardKatie: Abstract Accepted !! #Rome2019 @OHBM so excited to present at my first conference 🙂🙂
2 Mar, 19
Excited to have 5 trainees present data @OHBM 2019 #Roma! #OHBM2019
2 Mar, 19
RT @JenniferKFerris: Abstract accepted for @OHBM 2019! 🇮🇹 🧠 🇮🇹 Super excited to present our developing method for diffusion imaging of non-…
2 Mar, 19
RT @Ronan_Denyer: Looking forward to presenting some imaging x motor behaviour data at @OHBM Roma 2019! @UBC_BrainLab #OHBM2019
2 Mar, 19
RT @jy_schmidt: Findings from my #TMS #paediatric #concussion research presented 27 Feb (tomorrow) 4pm, symposium at #BrainStimConf! Thanks…
1 Mar, 19
RT @jasonlneva: The effects of acute exercise on visuomotor adaptation, learning, and inter-limb transfer. Excited to have this paper out i…
21 Feb, 19
.@laboyd47, @kimschon and Rachel Weber discuss how Neuroscience can contribute to the improvement of educational pr… https://t.co/YAo3OrJz6A
17 Nov, 18
RT @Ronan_Denyer: Enjoyed participating in the Educational Neuroscience Forum yesterday here @UBC. Lot's of interesting ideas and productiv…
16 Nov, 18
RT @BimalLakhani: Our team continues to grow! Calling all clinicians to join an exciting new #neurorehab clinic that will open its doors in…
24 Oct, 18